These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34627187)

  • 1. The detection of specific hypermethylated WIF1 and NPY genes in circulating DNA by crystal digital PCR™ is a powerful new tool for colorectal cancer diagnosis and screening.
    Overs A; Flammang M; Hervouet E; Bermont L; Pretet JL; Christophe B; Selmani Z
    BMC Cancer; 2021 Oct; 21(1):1092. PubMed ID: 34627187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer.
    Roperch JP; Incitti R; Forbin S; Bard F; Mansour H; Mesli F; Baumgaertner I; Brunetti F; Sobhani I
    BMC Cancer; 2013 Dec; 13():566. PubMed ID: 24289328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.
    Garrigou S; Perkins G; Garlan F; Normand C; Didelot A; Le Corre D; Peyvandi S; Mulot C; Niarra R; Aucouturier P; Chatellier G; Nizard P; Perez-Toralla K; Zonta E; Charpy C; Pujals A; Barau C; Bouché O; Emile JF; Pezet D; Bibeau F; Hutchison JB; Link DR; Zaanan A; Laurent-Puig P; Sobhani I; Taly V
    Clin Chem; 2016 Aug; 62(8):1129-39. PubMed ID: 27251038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients.
    Liu X; Fu J; Bi H; Ge A; Xia T; Liu Y; Sun H; Li D; Zhao Y
    BMC Cancer; 2019 Dec; 19(1):1212. PubMed ID: 31830937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
    Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
    Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating-tumour DNA methylation of HAND1 gene: a promising biomarker in early detection of colorectal cancer.
    Shavali M; Moradi A; Tahmaseb M; Mohammadian K; Ganji SM
    BMC Med Genomics; 2024 Apr; 17(1):117. PubMed ID: 38689296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
    Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
    Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
    [No Abstract]   [Full Text] [Related]  

  • 8. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.
    Bachet JB; Bouché O; Taieb J; Dubreuil O; Garcia ML; Meurisse A; Normand C; Gornet JM; Artru P; Louafi S; Bonnetain F; Thirot-Bidault A; Baumgaertner I; Coriat R; Tougeron D; Lecomte T; Mary F; Aparicio T; Marthey L; Taly V; Blons H; Vernerey D; Laurent-Puig P
    Ann Oncol; 2018 May; 29(5):1211-1219. PubMed ID: 29438522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer-a clinical biomarker discovery and validation study.
    Jensen SØ; Øgaard N; Ørntoft MW; Rasmussen MH; Bramsen JB; Kristensen H; Mouritzen P; Madsen MR; Madsen AH; Sunesen KG; Iversen LH; Laurberg S; Christensen IJ; Nielsen HJ; Andersen CL
    Clin Epigenetics; 2019 Nov; 11(1):158. PubMed ID: 31727158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer.
    Luo H; Zhao Q; Wei W; Zheng L; Yi S; Li G; Wang W; Sheng H; Pu H; Mo H; Zuo Z; Liu Z; Li C; Xie C; Zeng Z; Li W; Hao X; Liu Y; Cao S; Liu W; Gibson S; Zhang K; Xu G; Xu RH
    Sci Transl Med; 2020 Jan; 12(524):. PubMed ID: 31894106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
    Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
    Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a liquid biopsy based purely quantitative digital droplet PCR assay for detection of MLH1 promoter methylation in colorectal cancer patients.
    Wang D; O'Rourke D; Sanchez-Garcia JF; Cai T; Scheuenpflug J; Feng Z
    BMC Cancer; 2021 Jul; 21(1):797. PubMed ID: 34243735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study.
    Sui J; Wu X; Wang C; Wang G; Li C; Zhao J; Zhang Y; Xiang J; Xu Y; Nian W; Cao F; Yu G; Lou Z; Hao L; Liu L; Li B; Zhang Z; Cai S; Liu H; Lan P; Zhang W
    Clin Epigenetics; 2021 Feb; 13(1):26. PubMed ID: 33536049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients.
    Boeckx N; Op de Beeck K; Beyens M; Deschoolmeester V; Hermans C; De Clercq P; Garrigou S; Normand C; Monsaert E; Papadimitriou K; Laurent-Puig P; Pauwels P; Van Camp G; Taly V; Peeters M
    Clin Colorectal Cancer; 2018 Jun; 17(2):e369-e379. PubMed ID: 29605591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated DNA mutation detection in individuals undergoing colonoscopy.
    Fleshner P; Braunstein GD; Ovsepyan G; Tonozzi TR; Kammesheidt A
    Cancer Med; 2018 Jan; 7(1):167-174. PubMed ID: 29125240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature.
    Nicolazzo C; Barault L; Caponnetto S; De Renzi G; Belardinilli F; Bottillo I; Bargiacchi S; Macagno M; Grammatico P; Giannini G; Cortesi E; Di Nicolantonio F; Gazzaniga P
    Cancer Lett; 2021 Jun; 507():89-96. PubMed ID: 33744389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
    Haupts A; Roth W; Hartmann N
    Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.